GenScript x Lilly TuneLab: AIDD Is Rewriting Life-Science Services from Projects to Data Streams

GenScript partnered with Lilly's AI drug-discovery collaboration platform Lilly TuneLab in September, providing wet-lab services — protein expression, purification and characterisation — to platform members. Its 30 October investor day revealed the numbers that matter: revenue from a single research site of a global top-20 pharma grew 5x year on year in H1, AIDD S2D (sequence-to-data) services rose from 23% to 64% of that client's revenue mix, and candidate molecules awaiting validation per round jumped from hundreds to 1,000-5,000. AI-native clients are not just adding orders — they are changing the pricing structure.

According to CLS (Cailianshe) on 1 November, the partnership between GenScript Biotech and Lilly's AI/machine-learning drug-discovery platform Lilly TuneLab has become the clearest case study of how AIDD is rewriting the CXO business model: GenScript provides protein expression, purification and characterisation services to TuneLab members, converting AI predictions into biological validation data. CFO Jing Zhou put it bluntly — AIDD changes not just where demand comes from but how often and how deeply customers engage; life-science services are shifting from 'project-oriented delivery' to 'high-frequency, data-driven workflows'.

The investor-day numbers: S2D from 23% to 64%

The figures GenScript disclosed at its 30 October investor day are more persuasive than concept-level debate. For a single research site of a global top-20 pharma, GenScript's related service revenue expanded to 5x the prior-year level in H1 2026; AIDD S2D (sequence-to-data) services climbed from 23% to 64% of that client's revenue mix — within about a year, the client's purchasing moved from 'buying projects' to 'buying data'. The scale is changing too: candidates requiring validation per round rose from several hundred to 1,000-5,000, with testing depth up 5x. A TechBio client's related revenue grew more than 30x year on year in H1, with Q3 order frequency and average batch size up more than 5x and 3x respectively.

A partnership network: Tamarind, NVIDIA, Thermo Fisher

TuneLab is not an isolated case. In August, GenScript formed a strategic partnership with AI molecular-design platform Tamarind Bio, linking AI-driven design with its wet-lab validation capabilities. In October it launched a life-science startup competition with NVIDIA, combining NVIDIA's AI compute with GenScript's experimental validation and data generation for AI-driven drug-discovery startups. Per Beijing News, GenScript has also signed a strategic memorandum with Thermo Fisher to further expand its AIDD early-research ecosystem. To carry the demand, GenScript completed a Hong Kong placement in September raising about HKD 2.327 billion net, with roughly 70% earmarked to expand AIDD platform capacity — centred on automated high-throughput wet-lab facilities and equipment upgrades.

The leader's view: WuXi sorts AI clients into two types

The same shift shows up in leading CXOs' filings. WuXi AppTec named AIDD/AI4S client demand in its Q3 report for the first time; on the earnings call management split AI-pharma clients into two groups: those developing around specific targets toward a preclinical candidate, with workflows similar to traditional pharma, and those relying on high-throughput, high-quality experimental platforms that generate large datasets to train algorithms and close the dry-wet loop. The latter, management said, 'have very different requirements for our labs and for project delivery', and with automated labs and customised workflows the company 'can quickly raise our data-delivery volume by multiple orders of magnitude'.

Editor's note: S2D productises validation capacity

The S2D construct deserves attention on its own: the client provides a sequence, the provider returns data, and everything in between — expression, purification, characterisation, assays — is packaged into a standardised, high-frequency repurchasable product. That differs fundamentally from traditional CRO project pricing and milestone billing: unit prices may be lower, but repurchase frequency, batch size and stickiness are entirely different. The signal for industry watchers: AIDD's value to CXOs is not 'more AI clients' but a restructured delivery model in which wet-lab capacity is priced for the first time as 'data capacity' rather than 'project capacity'. Two things to watch: whether S2D extends from protein targets to more complex modalities, and whether automated wet-lab unit economics hold — 70% of a HKD 2.327 billion placement is betting on exactly that.